公开(公告)号：US20170266146A1

公开(公告)日：2017-09-21

申请号：US15532116

申请日：2015-12-03

Applicant: MOR RESEARCH APPLICATIONS LTD.

Inventor： Zeev DVASHI ,  Ayala POLLACK

IPC: A61K31/223 ,  A61K9/00 ,  A61K31/40

CPC classification number: A61K31/223 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/40 ,  A61K38/05 ,  A61K45/06 ,  A61P25/28 ,  A61P27/02 ,  A61K2300/00

Abstract: This disclosure relates to compositions for use in treatment of Alzheimer's Disease, and/or a ocular and retinal degenerative disease, such as age related macular degeneration. The described compositions include effective amounts of LLMe, the hydrobromide form thereof, or functional derivatives thereof. Methods of treatment of a retinal degenerative disease of Alzheimer's Disease using the described compositions are also provided.

公开(公告)号：US20160114006A1

公开(公告)日：2016-04-28

申请号：US14894347

申请日：2014-05-29

Applicant: MOR RESEARCH APPLICATIONS LTD.

Inventor： Ayala POLLACK ,  Zeev DVASHI

IPC: A61K38/45 ,  A61K31/40

CPC classification number: A61K38/45 ,  A61K31/40 ,  A61K38/1709 ,  C12Y207/11025

Abstract: This disclosure relates to compositions for use in treatment of a retinal degenerative disease, such as age related macular degeneration. The described compositions include agents for activating p38 and/or JNK signaling through the activation of TAK1 in the retinal pigment epithelium of a subject diagnosed with the disease. Methods of treatment of a retinal degenerative disease using the described compositions are also provided.

Abstract translation: 本公开涉及用于治疗视网膜退化性疾病如老年性黄斑变性的组合物。 所描述的组合物包括通过在诊断患有该疾病的受试者的视网膜色素上皮中激活TAK1来激活p38和/或JNK信号传导的药剂。 还提供了使用所述组合物治疗视网膜退行性疾病的方法。